Literature DB >> 21422138

Essay for the CIHR/CMAJ award: the role of low-molecular-weight heparin therapy venous thromboembolism.

Russell Hull1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21422138      PMCID： PMC3071416          DOI： 10.1503/cmaj.110364

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  14 in total

1.  Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin.

Authors:  D Green; R D Hull; R Brant; G F Pineo
Journal:  Lancet       Date:  1992-06-13       Impact factor: 79.321

2.  Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms.

Authors:  Russell D Hull; Graham F Pineo; Rollin F Brant; Andrew F Mah; Natasha Burke; Richard Dear; Turnly Wong; Roy Cook; Susan Solymoss; Man-Chiu Poon; Gary Raskob
Journal:  Am J Med       Date:  2007-01       Impact factor: 4.965

3.  Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer.

Authors:  Russell D Hull; Graham F Pineo; Rollin F Brant; Andrew F Mah; Natasha Burke; Richard Dear; Turnly Wong; Roy Cook; Susan Solymoss; Man-Chiu Poon; Gary Raskob
Journal:  Am J Med       Date:  2006-12       Impact factor: 4.965

4.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.

Authors:  S Schulman; C Kearon
Journal:  J Thromb Haemost       Date:  2005-04       Impact factor: 5.824

Review 5.  Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.

Authors:  J F van der Heijden; B A Hutten; H R Büller; M H Prins
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 6.  Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Harry R Büller; Giancarlo Agnelli; Russel D Hull; Thomas M Hyers; Martin H Prins; Gary E Raskob
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

Review 7.  Anticoagulation therapy for prevention and treatment of venous thromboembolic events in cancer patients: a review of current guidelines.

Authors:  Lars J Petersen
Journal:  Cancer Treat Rev       Date:  2009-09-16       Impact factor: 12.111

8.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.

Authors:  Agnes Y Y Lee; Mark N Levine; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Frederick R Rickles; Jim A Julian; Susan Haley; Michael J Kovacs; Michael Gent
Journal:  N Engl J Med       Date:  2003-07-10       Impact factor: 91.245

Review 9.  American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

Authors:  Gary H Lyman; Alok A Khorana; Anna Falanga; Daniel Clarke-Pearson; Christopher Flowers; Mohammad Jahanzeb; Ajay Kakkar; Nicole M Kuderer; Mark N Levine; Howard Liebman; David Mendelson; Gary Raskob; Mark R Somerfield; Paul Thodiyil; David Trent; Charles W Francis
Journal:  J Clin Oncol       Date:  2007-10-29       Impact factor: 44.544

10.  Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.

Authors:  R Hull; J Hirsh; R Jay; C Carter; C England; M Gent; A G Turpie; D McLoughlin; P Dodd; M Thomas; G Raskob; P Ockelford
Journal:  N Engl J Med       Date:  1982-12-30       Impact factor: 91.245
View more
  1 in total

1.  100 years. Looking back. Skill, drive and luck: the discovery and development of heparin.

Authors:  Richard Norman
Journal:  CMAJ       Date:  2011-11-28       Impact factor: 8.262
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.